Moderna, Inc. (MUN:0QF)
| Market Cap | 9.81B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 149 |
| Open | 25.14 |
| Previous Close | 24.99 |
| Day's Range | 24.77 - 25.20 |
| 52-Week Range | 20.18 - 46.34 |
| Beta | n/a |
| RSI | 54.94 |
| Earnings Date | Feb 20, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
XOMA Royalty Enters into Agreement to Acquire Generation Bio
- Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio’s collaboration with Moderna - - Generation Bio’s cell-targeted lipid nanoparticles (ctLNP) deliv...
Moderna Options Trading: A Deep Dive into Market Sentiment
Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ: MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled...
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine
Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in t...
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the ...
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA)
mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) mNEXSPIKE will be available in the...
ImmunityBio, Novo, Moderna among winners of EU drug recommendations this week
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges
Short bets on S&P 500 Healthcare sector rises to 2.12% in November; MRNA stays most shorted stock
The S&P 500 Healthcare sector (XLV) experienced a rise in average short interest during November, moving from 1.97% to 2.12%. Within this sector, Moderna (MRNA) remains the most heavily shorted stock....
Moderna on track to extend gains for the seventh straight trading day
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Moderna (MRNA) Q4 2024 Earnings Call Transcript
Is the Market Bullish or Bearish on Moderna Inc?
Moderna Inc's (NYSE: MRNA) short interest as a percent of float has risen 5.79% since its last report. According to exchange reported data, there are now 68.08 million shares sold short , which is 21...
MRNA January 2026 Options Begin Trading
Investors in Moderna Inc (Symbol: MRNA) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MRNA option...
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Moderna (MRNA) Q3 2024 Earnings Call Transcript
Moderna (MRNA) Q1 2025 Earnings Call Transcript
Moderna (MRNA) Q1 2025 Earnings Call Transcript
Moderna (MRNA) Q2 2025 Earnings Call Transcript
Moderna (MRNA) Q2 2025 Earnings Call Transcript
Moderna (MRNA) Q3 2025 Earnings Call Transcript
Moderna (MRNA) Q3 2025 Earnings Call Transcript
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
Moderna (MRNA) Faces Challenges Amid Declining Vaccine Research Funding
Moderna (MRNA) Faces Challenges Amid Declining Vaccine Research Funding
U.S. in "big danger" of falling behind in vaccine tech amid funding cuts, skepticism: Moderna co-founder
Moderna (MRNA) Under Scrutiny as FDA Investigates Vaccine Safety
Moderna (MRNA) Under Scrutiny as FDA Investigates Vaccine Safety
Moderna (MRNA) Just Reclaimed the 200-Day Moving Average
Is it a good or bad thing when a stock surpasses resistance at the 200-day simple moving average?
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
MRNA Makes Bullish Cross Above Critical Moving Average
In trading on Friday, shares of Moderna Inc (Symbol: MRNA) crossed above their 200 day moving average of $27.68, changing hands as high as $27.75 per share. Moderna Inc shares are currently trading up...